Citigroup Initiates Coverage on POZEN Inc (POZN) with a Buy
More News related to GSK
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Severe Reactions Spur GlaxoSmithKline to Pull Batch of H1N1 Swine Flu Vaccine in Canada, an Industrial Info News Alert
- Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
More News related to POZN
- POZEN to Host Investor and Analyst Event on December 8, 2009
- POZEN to Host Investor and Analyst Event on December 8, 2009
- POZEN Announces Start of Enrollment For PA32540 Phase 3 Program
- POZEN To Present at the Credit Suisse Healthcare Conference
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
More News related to New Coverage
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
Citigroup initiates coverage on POZEN Inc (Nasdaq: POZN) with a Buy. Price target $28.
Citigroup analyst says, " We believe Trexima provides several synergies/benefits to a class of products
called triptans, the current standard of care for the acute treatment for migraine headaches, which has a stable $2-billion market in the United States. Imitrex, marketed by Glaxo (NYSE: GSK), is the leader in the triptan market, with 2006 U.S. sales of $1.1 billion. Based on Phase III clinical trials, Trexima
has demonstrated superior efficacy to Imitrex alone with a comparable safety profile. Therefore, we believe Trexima will be the new gold standard treatment of migraine headaches."
Related Categories
New CoverageStocks Mentioned
+0.31
-0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
